Tricyclic Sulfonamides for Selective PP2A Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein phosphatase 2A (PP2A) has been largely ignored for drug development due to its broad substrate specificity and associated toxicity, limiting its therapeutic potential in treating various diseases, including cancer, neurodegeneration, and inflammation, as existing treatments often have adverse effects on the CNS and cardiovascular systems.
Innovation Solution
Development of tricyclic compounds that activate PP2A, offering anti-proliferative effects without inhibiting amine transporters or affecting GPCR-mediated pharmacology, allowing for targeted therapy in cancer and other conditions by modulating PP2A pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PP2A is activated as a therapeutic target, then anti-proliferative effects and tumor suppression are improved, but toxicity and adverse effects on CNS and cardiovascular systems worsen
Solution Approach 1:
The patent applies local quality by developing tricyclic compounds with specific molecular structures (formula I) that selectively activate PP2A in cancer cells while avoiding non-specific activation that causes toxicity. The compounds are designed with specific substituents (X1, X2, Y groups) that confer selective pharmacological activity, allowing therapeutic efficacy in tumors without systemic toxicity.
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical structure of tricyclic compounds through systematic variation of substituents at specific positions (X1, X2, Y groups). This structural parameter optimization enables tuning of PP2A activation potency and selectivity, achieving effective tumor suppression while minimizing off-target effects and toxicity.
2Reliability
If existing PP2A inhibitors are used, then anti-proliferative effects are improved, but adverse effects on CNS and cardiovascular systems worsen
Solution Approach 1:
The patent inverts the conventional approach by developing PP2A activators rather than inhibitors. This inversion allows restoration of PP2A function in cancer cells, which are often characterized by PP2A inactivation, thereby achieving anti-proliferative effects without the harmful side effects associated with PP2A inhibition, particularly in CNS and cardiovascular systems.
Solution Approach 2:
The patent converts the harmful effect of PP2A inactivation in cancer cells into a therapeutic opportunity. By developing activators that restore PP2A function, the patent transforms the disease-associated loss of PP2A activity into a beneficial therapeutic effect, achieving tumor suppression without the toxicity of conventional inhibitors.
3Adaptability or versatility
If broad substrate specificity of PP2A is utilized, then coordination of multiple signaling pathways is improved, but lack of substrate specificity control worsens
Solution Approach 1:
The patent applies universality by developing tricyclic compounds that activate PP2A to simultaneously inhibit multiple signaling pathways (PI3K-AKT, MAPK, mTOR, FOXO). This multi-functional activation approach allows coordination of diverse cellular processes including cell cycle control, differentiation, proliferation, and apoptosis, achieving broad therapeutic effects through a single mechanism.
Data Source
AI summary
Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine and dibenzoazepine compounds and similar genera: